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Thumb ECGs
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Hani Annabi and Jo Ann LeQuang
Abstract
Atrial fibrillation (AF) may be underdiagnosed, and there is much that remains 
unknown about this prevalent and potentially life-threatening arrhythmia. AF epi-
demiology has been thwarted in part by the fact that about a third of patients with 
AF have no symptoms, those with symptoms may experience them intermittently or 
have vague symptoms, and it can be challenging to capture an episode on a 12-lead 
ECG, which is required for diagnosis. There are many significant knowledge gaps in 
our understanding of AF etiology and progression. A new user-friendly device that 
allows for frequent self-monitoring of the heart rhythm has been introduced. With 
the thumb ECG, patients can record a tracing multiple times a day. A smartphone 
app will soon allow them to interact with their healthcare providers about these 
ECG recordings. An ECG parser will allow for an algorithm-directed, rapid, auto-
matic interpretation of these recordings with high specificity and sensitivity. This 
may help researchers learn more about the so-called silent AF, AF progression (and 
possible remission), and risk factors for AF. This technology holds great promise for 
patient care as well as for research into AF.
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1. Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia and 
associated with a fivefold increased risk of stroke and a threefold increased risk 
of heart failure; thus, AF is a major cause of cardiovascular morbidity [1–3]. 
The European Society of Cardiology (ESC) recognizes five main types of AF: 
first diagnosed episode, paroxysmal, persistent, long-standing persistent, and 
permanent [3] (see Table 1). It had long been thought that AF begets AF and 
the arrhythmia followed a linear forward progression from short, infrequent, 
self-terminating episodes to more persistent forms of AF, but that paradigm has 
been challenged in that about 3% of patients seem to have paroxysmal AF that 
never advances to more persistent forms [4]. It is now recognized that AF may 
plateau, remit/relapse, and one patient can simultaneously have multiple types 
of AF [5]. The ESC has also identified seven clinical types of AF, as the etiology 
of AF may relate to any of multiple mechanisms (see Table 2). In addition to 
types and categories of AF, the arrhythmia burden is frequently used as a metric 
to describe the amount of time an individual spends in AF [6].
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Despite the vast healthcare resources required to manage AF, little epidemiologi-
cal research has been conducted for this arrhythmia. AF can be an elusive arrhyth-
mia and short episodes can be difficult to capture on conventional ECGs. New 
technological innovations, including the thumb ECG, may offer tools to help better 
understand this arrhythmia. The thumb ECG opens up new technological abilities 
to benefit patients and individual cases of AF as well as to benefit research to better 
understand the epidemiology and natural history of AF in real-world populations.
Clinical type Characteristics Comments
AF secondary to 
structural heart 
disease
May occur in patients with left-ventricular 
systolic or diastolic dysfunction or other 
forms of structural heart disease
Treatment approaches vary; 
anticoagulation therapy
Focal AF AF paroxysms associated with localized 
triggers, such as the pulmonary veins
Pulmonary vein ablation may 
be considered; anticoagulation 
therapy
Polygenic AF Genetic, early onset Much remains to be elucidated 
about this type of AF; 
anticoagulation therapy
Postoperative AF Occurs following cardiac or other surgery 
in patient without prior history of AF
This AF may remit on its own, 
may persist or progress; treatment 
varies
AF with atrial 
remodeling
AF typically associated with mitral 
stenosis and/or mitral valve surgery or 
other forms of valvular disease
Atria remodel in response 
to arrhythmic burden; 
anticoagulation therapy
Athlete’s AF AF, often paroxysmal, that occurs during 
intense athletic training
Appears to be related to intensity 
of exertion
Monogenic AF Associated the cardiomyopathy and 
channelopathy
Anticoagulation therapy
Therapeutic interventions, when appropriate, are typically grouped as those involved rate control (allowing AF to 
continue but preventing a rapid ventricular response) or rhythm control (converting to sinus rhythm when possible).
Table 2. 
Clinical types of AF as defined by the European Society of Cardiology [3].
Types of AF Definition Treatments
First diagnosed Newly identified AF of any type Varies, depending on how severe the 
AF is and if the patient is symptomatic
Paroxysmal Sudden onset, self-terminating episodes 
that typically last a few moments to as 
long as 48 h; recurrent
Episodes terminate with or without 
intervention; may be asymptomatic
Persistent AF that lasts more than 7 days but can be 
converted with medical intervention
Pharmacological or electrical 
cardioversion
Long-standing 
persistent
AF that lasts a year or more and for which 
treatment is available
Catheter-based ablation, open ablation, 
drug therapy
Permanent AF that has lasted more than a year and 
which is accepted by patient and medical 
team
Rate control
These distinctions are based primarily on the duration of AF.
Table 1. 
Main types of AF as set forth by the European Society of Cardiology [3].
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2. The challenge of AF epidemiology studies
The classic diagnostic assessments of AF require that documentation of the 
arrhythmia on a 12-lead ECG. An irregular pulse may cause a clinician to suspect AF, 
but the ECG is considered necessary for a diagnosis [7]. AF is characterized by irregu-
lar R-R intervals without discernible P-waves (except when the patient has concomi-
tant atrioventricular third-degree block). About a third of all individuals with AF 
are asymptomatic, with silent AF or subclinical AF [8]. Even when symptoms occur, 
they may be infrequent or diffuse. Historically, early efforts to quantify the incidence 
and prevalence of AF and to better understand its potential relationship to stroke, 
heart failure, and other conditions were hampered by the limitations of standard ECG 
technology, the episodic nature of AF, and the large proportion of patients who had 
vague or no symptoms. Unfortunately, the first manifestation of AF may be stroke.
Recording AF on a standard 12-lead ECG assumes both that the clinician 
suspects that the patient has AF and that the AF will occur during the ECG record-
ing. ECG monitoring is too elaborate and expensive for use in routine population 
testing, such as for epidemiological studies. Continuous ECG monitoring can be 
obtained in individual patients by a wearable Holter monitor, but such systems 
are cumbersome to patients and generate vast quantities of tracings that can be 
a burden to analyze. Holter monitors are typically used for 24 h or for a specific 
number of days, such as 7 days. Event recorders may also be used. The advent of 
diagnostic counters in cardiac implantable electronic devices (CIEDs) allowed 
physicians to monitor device-detected arrhythmias, including AF. CIED monitoring 
offered the advantage of beat-by-beat analysis. Clinicians could program a cutoff 
rate for high rate events on the atrial channels, usually in the lower range of 170–220 
beats per minute. This led to a shift in terminology in that these devices obtained 
date on atrial high-rate episodes (AHRE), which included ectopic atrial tachycardia, 
atrial flutter, as well as AF. Current dual-chamber CIEDs offer mode-switching 
algorithms, which can essentially turn off ventricular tracking during episodes 
of AHRE. Mode-switching algorithms in conventional pacemakers can identify 
AHRE with 98% sensitivity and 100% specificity [9]. The value of this beat-by-
beat monitoring first emerged in the Mode Selection Trial (MOST) in which 313 
patients (median age 74 years) with pacemakers to treat sinus node dysfunction 
were followed for 27 months, during which their pacemakers recorded AHRE when 
atrial activity occurred at a rate > 220 beats per minute for more than 5 minutes 
[10]. More than half (51.3%) had AHRE, which in turn could be associated with 
elevated morbidity (stroke, permanent AF) and mortality [10]. The asymptomatic 
atrial fibrillation and stroke evaluation in pacemaker patients and atrial fibrillation 
reduction atrial pacing trial (ASSERT study) evaluated 2580 patients over age 65 
with hypertension but without a history of AF who had a pacemaker or ICD with 
an atrial lead. In the first 3 months of follow-up, 10.1% of patients had documented 
subclinical AF lasting over 6 min; at 2.5 years, subclinical AF occurred at least once 
in 34.7% of patients. The patients with subclinical AF had a 2.49-fold increased risk 
of stroke compared to patients who did not have subclinical AF, irrespective of any 
other atrial arrhythmias [11]. In a study of 356 pacemaker patients with continu-
ous atrial-channel monitoring, 88.2% had paroxysmal AF and 50.3% had at least 
one episode of persistent AF [12]. A study of 678 pacemaker patients (411 without 
AF and 267 with known AF) were followed over 38 months, and it was found that 
30% of those with no history of prior AF had silent AF [13]. Of course, the patient 
populations for these studies were limited to those with specific device indications 
(and in some cases other inclusion criteria), and therefore, these findings are not 
generalizable to the population as a whole.
Cardiac Pacing and Monitoring - New Methods, Modern Devices
4
As might be intuitively expected, the accuracy of AHRE detection improves with 
more continuous monitoring [14]. The high prevalence of AHREs detected by device 
diagnostics gave rise to the implantable loop recorder (ILR). The ILR relies on a detec-
tion algorithm to identify AF typically based on R-R interval stability as evidenced by 
consecutive QRS complexes. AF detection algorithms in ILRs are undergoing refine-
ment and may change in the future to improve specificity and sensitivity. As with a 
CIED, an ILR would be implanted only in patients who are suspected of having AF or 
other arrhythmias. The TRENDS study was an observational trial (n = 2486), which 
followed patients with an ILR for a mean of 1.4 years and analyzed them for atrial tachy-
cardia and AF burden and thromboembolic events and found 45% of patients with no 
prior history of AF (n = 1988) had subclinical episodes of atrial tachycardia [15].
The incidence and prevalence of AF may be vastly underestimated because there 
was until recently no reliable and accurate way to monitor patients who were not at 
specific risk for AF or who did not have a device or ILR indication. In other words, 
till now, AF data were gathered mainly from people with or at an elevated risk for 
arrhythmias. Epidemiological information on AF progression (from paroxysmal 
to persistent and permanent), risk factors for AF, and AF associations remain to be 
elucidated. Statistical analyses and meta-analyses have allowed certain risk factors for 
AF to emerge, such as hypertension, heart failure, coronary artery disease, valvular 
disease, diabetes mellitus, obesity, and chronic renal failure [16–18] as well as risk 
factors for AF progression, including older age and hypertension [19]. The thumb 
ECG offers an excellent opportunity to gather real-world data on AF from general and 
specific populations. Some important questions about AF remain to be elucidated:
• What is the actual incidence and prevalence of AF in the general population?
• Are there specific subpopulations with a higher prevalence of AF, for example, 
patients with diabetes, myocardial infarction, and cancer patients?
• What is the association between silent AF and stroke, for example, how many 
patients with silent AF are needed to have one patient suffer a stroke?
• What is the trajectory of AF—does it always progress? Can we define its course 
in clinically meaningful ways?
• Can patients with a low AF burden plateau for a long period of time at that level 
or does AF typically advance to increase the AF burden?
• What can be known about the population who has more than one type of AF at 
the same time (for example, both paroxysmal and persistent long-standing AF)? 
Do multiple types of concurrent AF confer worse morbidity and mortality?
• Can we better identify risk factors for AF?
In addition to these questions, it would be important to be able to better evaluate 
treatment strategies for AF by monitoring patients following drug therapy, abla-
tion, or other procedures.
3. The thumb ECG
The thumb ECG is a small-format, patient-friendly device that lay persons can 
use to monitor their heart rhythm. After reading the instructions or a brief training, 
5Atrial Fibrillation and the Role of Thumb ECGs
DOI: http://dx.doi.org/10.5772/intechopen.83660
individuals can use the thumb ECG on their own quickly and conveniently many 
times over the course of a day. The thumb ECG is a miniaturized and digital descen-
dant of the original ECG technology that was available around 1900. Patients can 
monitor their heart rhythm by pressing the device to the chest or by placing their 
thumbs on pads at the top of the device for a reading (see Figure 1). Several thumb 
ECG devices are available, and it is likely more are in development. Among them, the 
Coala Heart Monitor™ has been approved for use in Europe to individual patients 
in 2016 as a Class IIa medical device and to professional organizations in 2017. The 
device is connected to a cloud-based service to which users subscribe. When infor-
mation is uploaded from the thumb ECG to the cloud, it is automatically analyzed for 
AF or other arrhythmias using proprietary algorithms. Devices are available for use 
by multiple patients at a clinic but may also be purchased direct-to-consumer (the 
Coala Heart Monitor Pro™ and the Coala Heart Monitor™, respectively). The Coala 
device is connected via wireless Bluetooth connectivity to a smartphone for use with 
a proprietary Coala app. In this way, the thumb ECG dispenses with chest electrodes 
or other adhesive patches. An ECG may take up to 60 s.
The patient can view the individual ECG recordings and results from automated 
analysis directly on their smartphone app. Messages from the clinic to the patient 
can also be viewed directly on the app for feedback. ECG recordings can also 
be stored or printed by the patient to keep on hand for their next appointment. 
Patients can also add a special heart report service to their smartphone to discuss 
their ECG recordings with trained nurses for recommended actions. In this way, 
one centralized and highly specialized healthcare function may provide first-line 
primary cardiac healthcare coverage for a large and geographically spread-out 
population.
Clinicians monitor the results from their patients’ thumb ECG devices by access-
ing a secure portal via an ordinary laptop computer. The proprietary algorithms for 
ECG analysis are based on the ECG Parser, an algorithm system. The ECG Parser 
identifies specific beats and patterns of beats and groups them into classes by 
Figure 1. 
The Coala Heart Monitor™. Device sensors detect the heart rhythm when the device is placed on the chest or 
when the device is grasped with the thumbs on top of the two sensors on the device. Drawing: Courtesy of Todd 
Cooper.
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morphology; using the sequence of beats, the algorithm applies markers to ranges, 
measures intervals based on averaged beats, and then categorizes each signal or 
signal segment into one of the 12 different categories to facilitate their use in large 
databases (see Table 3).
4. The role of the thumb ECG in AF research
The ability to easily and inexpensively obtain ECG data has opened up new 
avenues to advance research into AF and other arrhythmias.
4.1  The role of premature atrial contractions and premature ventricular 
contractions in arrhythmogenesis
It has long been suspected that premature atrial contractions (PACs) and 
premature ventricular contractions (PVCs) may be associated with arrhythmias. 
However, since PACs and PVCs typically occur without warning and as isolated 
events, there has been no way to obtain appropriate data to investigate this ques-
tion without generating an overwhelming volume of tracings. A study published in 
2012 attempted to explore the relationship of PACs and PVCS to AF by evaluating 
428 patients without structural heart disease and with no history of AF using 24-h 
Holter monitoring [20]. This study found that frequent PACs were indeed signifi-
cant predictors of AF (p < 0.001). However, the study required patients to wear 
Holter monitors and the investigators had to analyze hundreds of hours of ECGs. 
A similar study was undertaken using thumb ECG technology that could analyze 
40,000 measurements over a span of 500 days. This second study was able to 
likewise confirm that frequent PACs were indeed highly significant predictors of AF 
(p < 0.001) [21] (see Figure 2).
Furthermore, with thumb ECG technology, it was relatively straightforward 
to confirm that the rate of VES and SVES events increased as AF developed [21] 
(see Figure 3).
Category Description Does this indicate AF?
0 Poor quality No
1 Normal No
2 Atrial fibrillation Yes
3 Pause/AV block II No
4 Fast, regular No
5 Long-short sequences No
6 Bigeminy No
7 Trigeminy No
8 More than 5 supraventricular extrasystoles No
9 More than 5 ventricular extrasystoles No
10 Irregular rhythm with P-waves No
Table 3. 
The Coala Heart Monitor™ system is based on an ECG parser with a proprietary and algorithmic system to 
help categorize arrhythmias automatically (Category 2 events indicate AF based on R-R interval dispersion 
and the absence of P-waves).
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4.2 The real-world incidence and prevalence of AF
The StrokeStop I study was aimed at evaluating the risk of stroke in people 
with untreated AF. To accomplish the study, systematic ECG screenings would 
be needed from over 7000 patients. A thumb ECG system was used to obtain 
intermittent ECG recordings, which were then analyzed using a proprietary ECG 
Figure 2. 
The incidence rates for development of AF based on number of ventricular extrasystoles (VES) and 
supraventricular extrasystoles (SVES). Chart: Courtesy of Coala Life.
Figure 3. 
As patients developed AF, the incidence of both ventricular extrasystoles and supraventricular extrasystoles 
increased sharply. Chart: Courtesy of Coala Life.
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parser system. In the group of patients aged 75 or 76 years, AF prevalence was 
found to be 12.3% [22]. This differs markedly from medical records, which found 
that in that particular patient group, 9.3% had a prior diagnosis of AF. Thus, 
thumb ECG with the ECG parser technology was able to confirm a much higher 
AF prevalence than was previously determined. This suggests that the actual 
incidence and prevalence of real-world AF may be substantially underestimated, 
which has implications for public health and the healthcare system as well as for 
individual patients.
In the ongoing Study of Men Born in 1943, thumb ECGs were introduced in 
2014 to help assess AF prevalence. After eliminating patients who had died, 
declined to participate, were lost to follow-up, or had known permanent AF, 
patients were evaluated twice daily by thumb ECG (n = 479). The thumb ECG in 
this study was able to diagnose a previously silent form of AF in 1.8% of patients 
(n = 8), and it found the overall prevalence of AF was 3.1% (95% confidence 
interval [CI], 1.83 to 4.98), but for men over the age of 71, the prevalence of 
paroxysmal AF was 9.9% [23].
In a study of 1510 patients aged 65 with risk factors for stroke, the use of thumb 
ECGs over a two-week period found undiagnosed AF in 0.9% of the population, 
which worked out for a total AF prevalence in the study group of 7.6% [24].
5. Thumb ECGs versus other types of monitoring
Ambulatory assessment using Holter monitors was previously the main 
way in which patients with suspected AF (and no implantable device) could 
allow the arrhythmia to go on the record for diagnosis. Holter monitors record 
ECGs from the patient around the clock and are typically set up to provide 
either 24 h or 7 days of data. Holter monitoring became the gold standard 
for arrhythmia analysis but had certain drawbacks: ambulatory monitoring 
utilizes a wearable technology that patients may find cumbersome, clumsy, 
and uncomfortable. Holter monitoring produces huge quantities of tracings to 
be analyzed. In a 7-day Holter monitoring program, each patient would yield 
168 h of ECG tracings (over 10,000 min per patient) and even with automated 
systems, this represented considerable time and effort to analyze. Furthermore, 
in 168 h of ECG tracings, it was possible that only very short runs of AF 
would appear—for example, there might be 10 or 20 min of AF somewhere in 
10,000 min of data.
Subclinical device-detected AF is defined as an AHRE (>190 beats/min for 
>6 min and <24 h) with lack of prior diagnosis and correlated symptoms in patients 
with devices that can produce continuous ECG monitoring [25]. Continuous ECG 
monitoring has been shown to increase the number of undiagnosed episodes of AF, 
especially in those with prior bouts of ischemia [26]. In fact, thumb (or handheld) 
ECGs have been shown to be significantly more sensitive in the detection of silent 
AF compared to conventional 24-h Holter ECGs [27, 28].
In order to determine whether Holter monitors offered comparable efficacy 
to thumb ECGs, a study of 95 patients (≥65 years) was initiated. Patients were 
excluded if they had a history of AF. All patients were monitored for 5 days using a 
Holter monitor and concurrently with a thumb ECG twice daily. Patients continued 
using the thumb ECG for 30 days. Paroxysmal AF was detected in 20 patients using 
the thumb ECG, in 17 patients using the Holter monitor, and by both systems in 
10 patients [29]. The detection rates between the two methods did not differ in a 
statistically significant way (p = 0.63).
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In a study of 108 consecutive patients with ambiguous symptoms of dizziness 
and heart palpitations, patients were monitored using a Holter monitor for 24 h and 
then twice daily using a thumb ECG for 28 days. The mean age of patients in this 
study was 54.1 years. In this study, the thumb ECG was significantly more effective 
over 4 weeks at identifying AF and paroxysmal supraventricular tachycardia than 
the Holter monitor [30].
In a study presented at the Cardiovascular Spring Meeting in Stockholm in 
April 2018, researchers took 1000 consecutive, anonymous printouts of wave-
forms captured from the chest and thumbs using the Coala Heart Monitor™ 
system. No exclusions were allowed. Each printout consisted of three 10-s tracings 
recorded at 25 mm/s. Algorithm analysis notation and patient information (except 
patient sex and age by 10-year groups) were removed from the strips. However, 
heart rate, R-R median values, and user-provided annotations were allowed. 
All strips came from real-world patients using the Coala monitor; subjects were 
given no special device training. All strips were then sent to a trained cardiologist 
who interpreted each one manually and then compared his interpretation to the 
automatic analysis offered by the Coala device. One cardiologist interpreted all 
of the rhythm strips. When comparing these 1000 real-world ECGs to the Coala 
algorithm’s interpretation, it was found that the Coala was highly accurate with 
97% sensitivity and 95% specificity. The estimated prevalence of AF from these 
recordings was 14.4% [31, 32].
In the StrokeStop I study, 80,149 tracings were recorded using the Zenicor™ 
thumb ECG system; tracings were obtained from 3209 patients aged 75 or 76 years. 
It was found to offer 98% sensitivity and 88% specificity, and the use of thumb 
ECG technology combined with an ECG parser reduced the workload in analyzing 
data by over 85% [22].
In a study of 100 patients with AF, a 12-lead ECG recording was followed by 
a thumb ECG assessment with the results compared by a blinded investigator. 
When the 12-lead ECG was compared to the thumb ECG, the thumb ECG had a 
sensitivity of 96% and a specificity of 92% versus the 12-lead ECG. As part of the 
same study, a second group of patients (n = 12) underwent effective cardiover-
sion for AF and then used a thumb ECG to assess their rhythms twice a day for 
the next 30 days. In this group, 95% of cardioverted patients had tracings from 
the thumb ECG considered to be of sufficient quality for clinical diagnosis. A 
third group (n = 606) was screened for AF using the thumb ECG. Twelve people 
in this group were diagnosed with AF of whom six had no history of AF and no 
symptoms [33].
6. Questions about silent AF
One of the primary reasons to suspect that AF incidence and prevalence is 
underestimated is the fact that as much as 40% of AF may be asymptomatic [34, 35]. 
Clinically silent AF may occur with paroxysmal AF, persistent long-standing AF, or 
permanent AF [36]. Asymptomatic AF is not benign; data from the EORP-AF study 
found that asymptomatic AF conferred on patients a higher 1-year mortality risk than 
symptomatic AF [35] although the AFFIRM study found no such difference between 
symptomatic and asymptomatic AF patients [37]. Early and accurate diagnosis of AF 
may help reduce the burden of AF on the healthcare system and may allow interven-
tions to reduce morbidity and mortality associated with AF.
The classic AF symptoms may include any or a combination of the following: 
heart palpitations, sensations of a racing or pounding heart, dyspnea, chest pain or 
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discomfort, fatigue, lethargy, dizziness, malaise, anxiety, and syncope. Symptoms 
are thought to be caused primarily by rapid ventricular response to AF rather than 
by the atrial arrhythmia itself. It is thought that rapid ventricular activity, irregular 
rhythms, and the loss of the atrial contribution to ventricular filling might all 
contribute to reduced cardiac output, exacerbation of left-ventricular dysfunction, 
cardiac remodeling, and a general deterioration of overall health [36]. In addition 
to asymptomatic paroxysmal AF, some cases of AF may go unnoticed by patients 
because the AF episodes are brief and interspersed between long periods of normal 
sinus rhythm and symptoms may be very mild, diffuse, or overlooked by patients. 
Silent AF is typically an incidental diagnosis, which may occur during routine 
examinations or tests for other conditions.
The mechanical effects on the heart caused by fibrillating atria as well as the 
electrophysiological and neurological consequences of AF appear to be the same 
whether AF is clinically silent or symptomatic. Silent AF, like its symptomatic 
counterpart, is associated with silent or symptomatic emboli, heart failure, morbid-
ity, and mortality [38].
Risk factors for silent AF include patients with cryptogenic stroke, hypertension, 
advanced age, obesity, diabetes mellitus, cigarette smoking, chronic kidney disease, 
or a history of cardiac disease [7, 35, 39–42]. Blood group type 0 appears to confer a 
protective effect against thromboembolism in persons with AF for reasons that remain 
unclear, but which may be associated with circulating von Willebrand factor levels [43].
7. Anticoagulation therapy
AF has been clearly associated with the catastrophic complications of throm-
boembolism and cerebral stroke, but the association between AHRE and thrombo-
embolism/stroke is not well defined [44]. The thumb ECG, like CIEDs, can detect 
AHRE but it remains an open question as to whether and under what circumstances 
anticoagulation therapy is appropriate for patients with documented AHRE. AHRE is 
defined by two parameters: the atrial rate and the duration of the episode. However, it 
remains unclear as to how fast or how long an episode of AHRE must be to represent 
a risk of thromboembolism or stroke [45]. Thus, it remains to be elucidated at which 
point a patient with AHRE might benefit from anticoagulation therapy.
According to the ASSERT and TRENDS studies, the association between the 
formation of a thromboembolism and AHRE is challenged by the lack of a temporal 
relation between the two events [46, 47]. The current data are contradictory. In the 
ASSERT study, tachyarrhythmic episodes ≥6 min in duration have led to a higher 
embolic risk [11]. However, in the TRENDS study, tachyarrhythmic episodes ≤5.5 h 
were not associated with an increased thromboembolic risk [15].
With much to be elucidated about the potential role of anticoagulation therapy 
for patients with AHRE, thumb ECGs may play an important role. These devices 
may help uncover more about AHRE and its relationship to AF as well as its associa-
tion to adverse events. A more refined understanding of the temporal relationship 
between AF and its comorbidities will help to create more effective anticoagulation 
therapies and better outcomes.
8. Knowledge gaps about AF
The incidence and prevalence of AF may correlate with gender, age, comorbidities 
(such as heart failure, atherosclerosis, hypertension, diabetes mellitus, and others), 
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and possibly other variables. The natural course of AF, once thought to be the linear 
progression from paroxysmal to persistent to permanent, remains to be elucidated 
and appears to be more fluid than originally thought, even allowing for remission and 
relapsing. While the association between AF and stroke is clear and ominous, it is not 
known if this risk is greater, lesser, or the same for symptomatic versus asymptomatic 
AF or different types or clinical presentations of AF. A meta-analysis of data on AF 
showed that while men generally had a higher incidence of AF than women, women 
and, in particular elderly women, were at a greater risk than men for stroke and 
thromboembolism associated with AF [48–50]. Whether or not AF in the elderly and 
oldest old populations is associated with more or more severe symptoms also remains 
unknown. Greater understanding of these matters could result in better, more 
targeted, and more effective clinical approaches and treatment.
It has been observed that patients implanted with CIEDs may experience brief, 
clinically silent episodes of paroxysmal AF when the device is initially implanted. 
The Automatic Interpretation for Diagnosis Assistance (AIDA) study found that 
half (50.6%) of patients with de novo pacemaker implantations experienced atrial 
arrhythmias in the first month following implant and these episodes were often 
asymptomatic [51]. In a study of 213 dual-chamber pacemaker patients, all of them 
had experienced at least one atrial arrhythmia at 3 years following implant [52]. 
This area has not been studied extensively and it is not known if this is clinically 
important or might resolve with time [53].
Other knowledge gaps occur in the treatment of AF and how patients respond. 
It has been suggested that pharmacological suppression of AF may simply convert 
symptomatic AF into clinically silent AF, but there is not much data to support or 
refute this notion. While it is known that AF incidence and prevalence increases 
with age, it is not clear whether geriatric patients are more likely to have symptom-
atic or asymptomatic AF, nor has it been fully elucidated whether certain types of 
AF (such as permanent or persistent long-standing AF) occur more often in elderly 
patients.
AF is thought to be more prevalent in industrialized nations compared to devel-
oping countries but this has not been extensively studied [54].
Thumb ECG studies can provide robust data to help answer these questions 
by allowing the inexpensive and straightforward acquisition of large amounts of 
ECG data annotated with patient-reported symptoms from selected populations 
and, together with algorithms to analyze the data, provide for fast and accurate 
interpretation of that data. The advent of thumb ECG technology will empower 
medical science and the healthcare system to obtain vital information crucial to 
the early and accurate diagnosis of AF, particularly paroxysmal and clinically 
silent AF.
Thumb ECG data may help better guide anticoagulation therapy. 
Anticoagulation therapy is frequently prescribed for AF patients. In CIED 
patients with diagnostic data revealing atrial high-rate activity, it is not clear 
despite this documentation whether patients would benefit from anticoagulation 
therapy [38].
The populations affected by AF are diverse and include patients with valvular 
disease, malignancy, inflammation, atherosclerotic coronary artery disease, plus 
those with genetic forms of AF, postoperative patients, patients following ablations, 
CIED patients, along with patients who are geriatric, obese, or who have heart fail-
ure and/or hypertension. These populations are diverse, some overlap considerably, 
and cross the lines between medical disciplines [40]. These factors contribute to 
the confusion that makes it hard to better quantify AF. A number of open questions 
remain and a high-level summary appears in Table 4.
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9. The AF burden and thumb ECG technology
In an effort to better grapple with the global effects of AF on a patient, the AF 
burden is often used to better describe the arrhythmia and its consequences. The 
AF burden may be defined as how much time the patient spends in AF per unit of 
time (such as what proportion of 1 day or 1 week) [6]. AF burden lacks a universally 
recognized consensus definition, has not been extensively validated as a measure, 
and is not often used when evaluating AF cases in terms of severity or risk. It is not 
known if a high AF burden exacerbates risk factors for stroke. It is strongly sus-
pected that the AF burden is generally underestimated because of asymptomatic AF 
and the fact that conventional technologies have been used to assess the incidence 
and prevalence of AF [38]. A consensus definition would be helpful and would 
facilitate meaningful efforts to study how the AF burden affects the course of the 
arrhythmia, treatment options, and related morbidity and mortality.
10.  An integrated approach to care for AF patients using thumb ECG 
technology
A knowledge deficit about AF may be observed even in patients provided spe-
cific, patient-focused oral, and/or written educational tools [55, 56]. Individualized, 
Question Obstacles Comments
Which patient 
populations are at 
greatest risk from AF?
May require some kind of diagnostic 
algorithm to account for comorbidities; need 
to find definition of risk (risk of AF, stroke, 
mortality).
Likewise, an important 
unanswered question is which 
populations are at lowest risk? 
Why?
Can patients use thumb 
ECG technology to 
self-monitor and/or 
collect data?
Requires study parameters to be set up. May be most helpful means 
to get more accurate and 
comprehensive AF data.
What is the normal 
trajectory of AF?
Requires more data, also it is not clear if 
the natural course of AF might vary by 
population (for instance, it might be different 
in older than younger patients, or in men 
versus women).
The old paradigm that AF 
begets AF may not be true or 
may be only partially accurate.
Are some types of AF 
associated with greater 
morbidity and mortality 
than others?
Requires more data and possibly 
stratification.
This question could lead to 
more individualized treatment 
courses.
Can we reach a 
consensus definition for 
AF burden?
This is a relatively new term that is typically 
well understood but imperfectly quantified; 
need consensus definition.
It is not clear if and in what 
ways AF burden may relate 
to AF risks/outcomes. Once 
it is defined, it can be more 
efficiently studied.
Is silent AF always 
without symptoms?
Evidence that quality of life decreases in 
patients even with asymptomatic AF suggests 
that AF is almost always symptomatic but not 
all symptoms are recognized.
Better diagnostic tools are 
needed to identify silent AF 
and then to measure quality 
of life.
What is actual incidence 
and prevalence of AF?
Correlations with clinical presentation, type, 
history, duration, and patient characteristics 
may be helpful but challenging to obtain.
Will allow for more effective 
and individually targeted 
treatments.
Table 4. 
Key questions about AF that may be a good research topic with thumb ECG technology [40].
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educational interventions for AF have been proposed in order to address specific 
patient needs, for example, types of AF treatment, recommended lifestyle modi-
fications, possible self-management tools, and drug therapy [57]. Thumb ECG 
technology may soon emerge as an important element in the care of AF patients. 
Patients who are considered appropriate candidates to monitor their hearts using a 
thumb ECG device should be given specific training on the use of the device; such 
training would likely be brief as these devices are designed to be easy to use for lay-
people. The regular use of a thumb ECG can assist patients in arrhythmia detection 
and diagnosis as well as monitoring the course of treatment. The integration of the 
thumb ECG into AF patient care may empower the patient and be a cornerstone of a 
shared decision-making paradigm, in the event that multiple treatment options are 
considered. It is known that patient education, shared accountability, and indi-
vidual empowerment drive improved adherence [58]. The use of a thumb ECG may 
also be helpful in linking AF episodes to specific symptoms [3]. Furthermore, the 
thumb ECG may reveal subclinical AF and may help better delineate the progres-
sion of AF over time.
AF is so pervasive and crosses so many disciplinary boundaries that a multi-
disciplinary approach to care is warranted, bringing together several healthcare 
disciplines, i.e., general practitioners, cardiologists, surgeons, and allied health 
professionals along with nonspecialists who may advise on diet, lifestyle modifica-
tions, physical and occupational therapy, and stroke prevention tactics. Moreover, 
patients with newly diagnosed AF may benefit from a comprehensive cardiovas-
cular evaluation, including transthoracic echocardiography, as they are at risk for 
other cardiovascular conditions [59, 60].
AF treatment typically involves anticoagulation therapy (initiated early in 
appropriate patients), lifestyle modifications, and appropriate interventions, which 
could include the use of antiarrhythmic agents or other pharmacological treat-
ments, catheter-based interventions, or surgical procedures (ablation, left-atrial 
appendage occluders, etc.) [3]. Growing understanding of how altered calcium 
homeostasis, atrial fibrosis, ion-channel dysfunction, autonomic imbalance, and 
oxidative stress may contribute to AF combined with new knowledge about the 
genetic underpinnings of arrhythmias should all be taken into account when struc-
turing AF care programs [61]. As an example, pulmonary vein ablation has been 
recommended for some types of AF but would not benefit all AF patients. However, 
all AF patients are likely to benefit from regular, consistent, systematic care includ-
ing routine follow-up visits, monitoring overall physical condition, arrhythmia 
assessments, pharmacological adjustments as needed, and assessments and encour-
agement to promote treatment adherence. Thumb ECG monitoring would be an 
integral part of that care paradigm.
AF care can be defined by three broad domains: stroke prevention (anticoagulation 
therapy), rate control (mainly aimed at symptomatic improvement), and rhythm con-
trol (arrhythmia conversion). Pharmacological therapy can be an important element of 
AF care and varies based on the individual characteristics of the patient (age, target for 
treatment, comorbidities, symptoms, symptom severity, left-ventricular ejection frac-
tion, hemodynamics, other drugs the patient may be taking, and so on). Acute rhythm 
control can be achieved pharmacologically in up to half of all patients diagnosed 
with recent-onset AF by using antiarrhythmic agents. Antiarrhythmic drug therapy 
should be guided first by safety rather than effectiveness, and treatment goals should 
be established that seek symptomatic improvement with the foreknowledge that side 
effects with these drugs are common [3]. Dose reduction of antiarrhythmic agents may 
be needed for geriatric patients in that metabolism and the heart’s electrical system slow 
down with increasing age [62]. Above all, it should be noted that many antiarrhythmic 
agents have seemingly paradoxical pro-arrhythmic effects. This requires regular ECG 
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monitoring to protect patients against the onset of a new drug-induced arrhythmia [63]. 
While there are to date no studies on the role of thumb ECG technology in this setting, 
it makes intuitive sense that a thumb ECG may be useful for patients on antiarrhythmic 
drug therapy.
11. Future directions
The usefulness of the Coala Heart Monitor™ needs further validation with 
regard to specific patient groups. Currently, the TEASE study is evaluating patients 
with cryptogenic stroke for 28 days using the Coala Heart Monitor™ [64]. The 
rationale for prolonged monitoring in this population is warranted in order to deter-
mine if anticoagulation is indicated. Furthermore, the Red Heart Study is an initia-
tive using the Coala Heart Monitor™ exclusively among women with suspected AF 
or other arrhythmias [65].
While the thumb ECG has already proven its value as a tool for finding and 
following the progression of AF and other arrhythmias, it is beyond the functional-
ity of this device to assess structural heart changes or impaired left-ventricular 
function. However, some thumb ECG devices already on the market, such as the 
Coala Heart Monitor™, have the capacity to record simultaneously both chest 
ECG and heart sounds through an electronic stethoscope membrane. This allows 
derivation of acoustic cardiographic parameters such as systolic time intervals (STI) 
along with the presence and intensity of S3 and S4 heart sounds. The use of STI 
has historically proven to be a highly sensitive method of assessment of changes in 
left-ventricular function, albeit with inconclusive findings as a diagnostic tool for 
differential diagnosis [66, 67].
The use of acoustic cardiographic parameters derived from repeated patient-
engaged recordings performed in the home environment may, in this way, 
characterize and track changes in left-ventricular function at low cost and low 
burden to the healthcare system. Such indicative parameters of change in cardiac 
function may fully utilize the individualized data collected from many recordings 
over a period of time as a baseline rather than population-derived and regression-
corrected baseline data for improved sensitivity and accuracy.
In the future, the automatic algorithm-driven detection and reporting of sud-
den deviations in the patient’s heart rhythm may help reduce the human workload 
without compromising care, in that the healthcare provider at the clinic can 
be notified quickly about these deviations and take appropriate action, such as 
changing medications. It is plausible that this could all happen before the patient 
experiences any symptoms. In this way, small, highly specialized healthcare 
centers may provide first-line cardiac primary healthcare coverage with respect 
to AF or AF with left-ventricular dysfunction (e.g., decompensated heart failure) 
for a large and geographically widespread patient population. These centers 
would be centralized in terms of their function, but not necessarily geographi-
cally centralized.
Centralized data processing, ultimately with data from possibly millions of 
recordings, may provide for high detection accuracy and is an ideal application for 
machine learning or artificial intelligence, which could utilize pattern-recognition 
algorithms on these datasets to provide an early indication of any characteristic 
pathological developments, which can then be confirmed or ruled out in a tradi-
tional healthcare setting using conventional techniques and modalities. Continuous 
patient feedback through the smartphone, potentially even using gamification to 
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create a game-type application, may improve patient engagement and adherence 
to proposed lifestyle or dietary changes and pharmacological compliance. This 
platform may also be an ideal tool for running very large cost-effective clinical stud-
ies, in that data collection can take place using the thumb ECG. Patients can use the 
device and the smartphone app in the privacy of their own homes to track their own 
results and monitor symptoms. This could likely be done at a very low cost with 
few technical or logistical barriers. While visionary in concept, such a system may 
provide a unique solution for improved patient outcomes through early intervention 
and close follow-up of treatment with potential (and substantial) reductions in cost 
and resource utilization to the healthcare system.
12. Conclusions
AF is a prevalent arrhythmia that poses a significant burden on the healthcare 
system, but it is under-diagnosed in that it can be challenging to capture the 
arrhythmia on a 12-lead ECG (required for diagnosis), and up to a third of patients 
are asymptomatic. The thumb ECG offers an innovative, user-friendly approach to 
consistent cardiac self-monitoring that may provide new insights into the incidence 
and prevalence of AF. The use of pattern-recognition algorithms, artificial intel-
ligence, and smartphone apps may allow the thumb ECG both to facilitate care for 
cardiac patients in the future and to make large studies of arrhythmias more cost 
effective.
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